Highlights Tyra Biosciences, Inc.

Equities

TYRA

US90240B1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
18.99 ^USD	+4.86%		+11.90%	+37.11%

Jul. 02	Tyra Biosciences Plans to Develop Potential Treatment of Dwarfism, File Application in H2	MT
Jul. 02	Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tyra Biosciences Plans to Develop Potential Treatment of Dwarfism, File Application in H2	Jul. 02	MT
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia	Jul. 02	CI
Tyra Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Tyra Biosciences Q4 Net Loss Widens	Mar. 19	MT
Tyra Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy	Feb. 01	DJ
Tyra Biosciences, Inc. Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia	Feb. 01	CI
Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300	Dec. 22	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Tyra Biosciences Announces Fda Orphan Drug Designation for Tyra-300 for the Treatment of Achondroplasia	23-08-01	CI
Tyra Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-22	CI
Tyra Biosciences, Inc. Expects to Submit an Investigational New Drug Application to the U.S. Food and Drug Administration to Enable a Phase 2 Study of TYRA-300 in Pediatric Achondroplasia in 2024	23-03-22	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-22	CI
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia	23-03-01	CI
Tyra Biosciences, Inc. Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300	22-11-29	CI
Tyra Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tyra Biosciences, Inc.

Equities

TYRA

US90240B1061

Highlights

Filters